Drug intelligence / Profile preview

CT125B

Development stage: Phase 1
Lead developer: Beijing Gaobo Boren Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CT125B is a donor-derived CD5 CAR T cell therapy being investigated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. It works by targeting CD5, a surface antigen expressed on T-cells, enabling the engineered T-cells to recognize and attack malignant T-cells. The therapy involves collecting peripheral blood mononuclear cells from donors, engineering them to express a chimeric antigen receptor targeting CD5, and infusing these modified cells into patients after lymphodepletion with fludarabine and cyclophosphamide.

Other names: Donor-Derived CD5 CAR T

Targets

CD5 (T-cell surface glycoprotein CD5)

Beyond the preview

Go deeper on CT125B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT125B.

Explore the full profile